在撒哈拉以南非洲开展临床试验:马拉维隐孢子虫研究的挑战与经验
该文总结了在马拉维单一中心开展一项2A期随机双盲安慰剂对照氯法齐明治疗HIV感染者隐孢子虫病的试验中所遇到的挑战与经验。挑战涉及研究启动、研究人群、研究实施和文化问题,经验主要涉及监管体系和操作障碍,建议可推广至撒哈拉以南非洲的其他人体试验。
要点
- 在撒哈拉以南非洲开展符合ICH-GCP的人体试验面临资源与经验不足的双重挑战。
- 挑战可归纳为研究启动、研究人群、研究实施和文化问题四类。
- 成功实施需要周密规划、持续评估、对新进展的响应及对所有试验操作的监督。
核心结论
- 在撒哈拉以南非洲启动和实施人体试验具有挑战性,但存在解决方案。
- 成功执行需要周密规划、持续评估、对新进展的响应以及对所有试验操作的监督。
研究设计与样本
- 在马拉维单一中心开展的2A期随机双盲安慰剂对照试验,评估氯法齐明治疗HIV感染者隐孢子虫病。
- 本文报告该试验实施中的挑战与经验教训。
主要发现
- 主要挑战分为研究启动、研究人群、研究实施和文化问题四组。
- 经验教训主要涉及监管体系和操作障碍。
临床怎么用
- 建议可将经验应用于低收入和中等收入国家尤其是撒哈拉以南非洲的其他人体实验性试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An effective drug to treat cryptosporidial diarrhea in HIV-infected individuals is a global health priority. Promising drugs need to be evaluated in endemic areas which may be challenged by both lack of resources and experience to conduct International Committee of Harmonisation-Good Clinical Practice (ICH-GCP)-compliant clinical trials. METHODS: We present the challenges and lessons learned in implementing a phase 2A, randomized, double-blind, placebo-controlled trial of clofazimine, in treatment of cryptosporidiosis among HIV-infected adults at a single site in Malawi. RESULTS: Primary challenges are grouped under study initiation, study population, study implementation, and cultural issues. The lessons learned primarily deal with regulatory system and operational barriers, and recommendations can be applied to other human experimental trials in low- and middle-income countries, specifically in sub-Saharan Africa. CONCLUSION: This study demonstrated that initiating and implementing human experimental trials in sub-Saharan Africa can be challenging. However, solutions exist and successful execution requires careful planning, ongoing evaluation, responsiveness to new developments, and oversight of all trial operations.
引用
- Toto N, Douglas E, Gmeiner M, et al. Conducting clinical trials in sub-Saharan Africa: challenges and lessons learned from the Malawi Cryptosporidium study. Trials. 2020. PMID: 32711568. doi:10.1186/s13063-020-04620-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。